Evidence map›Paper›PMID 28054285›Full record

ReviewNeurocritical care2017

Drug Interactions in Neurocritical Care.

Brian Spoelhof, Salia Farrokh, Lucia Rivera-Lara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurocritical care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brian SpoelhofDepartment of Pharmacy, Lahey Hospital and Medical Center, Burlington, MA, USA. Brian.Spoelhof@lahey.edu.ORCID http://orcid.org/0000-0002-3339-9498
Salia FarrokhNeurocritical Care, Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA.
Lucia Rivera-LaraDepartment of Anesthesiology and Critical Care Medicine, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-drug interactions (DDIs) are common and avoidable complications that are associated with poor patient outcomes. Neurocritical care patients may be at particular risk for DDIs due to alterations in pharmacokinetic profiles and exposure to medications with a high DDI risk. This review describes the principles of DDI pharmacology, common and severe DDIs in Neurocritical care, and recommendations to minimize adverse outcomes. A review of published literature was performed using PubMed by searching for 'Drug Interaction' and several high DDI risk and common neurocritical care medications. Key medication classes included anticoagulants, antimicrobials, antiepileptics, antihypertensives, sedatives, and selective serotonin reuptake inhibitors. Additional literature was also reviewed to determine the risk in neurocritical care and potential therapeutic alternatives. Clinicians should be aware of interactions in this setting, the long-term complications, and therapeutic alternatives.

Indexed as

Drug InteractionsDrug-Related Side Effects and Adverse ReactionsAnti-Bacterial AgentsAnticonvulsantsCalcium Channel BlockersCritical CareHematologic AgentsHumansHypnotics and SedativesNervous System DiseasesSelective Serotonin Reuptake InhibitorsAnti-Bacterial AgentsAnticonvulsantsCalcium Channel BlockersHematologic AgentsHypnotics and SedativesSelective Serotonin Reuptake InhibitorsAdverse drug reactionsAntiepilepticsCalcium channel blockersDrug interactionsDrug metabolismNeurocritical care

Identifiers

PMID28054285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.